Thursday, September 29, 2011
SanBio Inc., of Mountain View, Calif., reported that the first subject in a Phase I/IIa trial has been treated with SB623. The two-site study will evaluate 18 patients who have suffered an ischemic stroke within the past six to 24 months and have a motor neurological deficit.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.